title: Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease.
abstract: OBJECTIVE
  To compare the occurrence of malignancy in patients with severe ocular inflammatory disease treated with systemic corticosteroids alone or with systemic immunosuppressive drugs with or without systemic corticosteroids.
  
  
  METHODS
  The clinical records of 543 patients with ocular inflammatory disease treated with systemic corticosteroids and/or immunosuppressive chemotherapy were reviewed in a retrospective cohort study. Characteristics of patients treated with corticosteroids alone were compared with characteristics of patients treated with immunosuppressive agents with or without preceding corticosteroid treatment. The rates of malignancy after initiation of drug therapy were compared using an exact test for incidence rate data.
  
  
  RESULTS
  Compared with patients treated with corticosteroids alone, patients treated with immunosuppressants with or without corticosteroid treatment were older and had more severe systemic disease. During a total of 1261 person-years of follow-up, a malignancy developed in five patients. The rate of malignancy in the immunosuppressant group (4 malignancies during 968 person-years of follow-up) was not significantly different from the rate in the corticosteroids alone group (1 malignancy during 293 person-years of follow-up) (P > 0.90, exact test for incidence rate data).
  
  
  CONCLUSIONS
  These findings do not support the hypothesis of an increased risk of malignancy in patients with severe ocular inflammatory disease who are treated with systemic immunosuppressive agents compared with patients treated with systemic corticosteroids.
authors.affiliation: Immunology & Uveitis Service, Massachusetts Eye & Ear Infirmary, Harvard Medical School, Boston, USA.
authors.forename: L
authors.initials: L
authors.lastname: Lane
authors.forename: R
authors.initials: R
authors.lastname: Tamesis
authors.forename: A
authors.initials: A
authors.lastname: Rodriguez
authors.forename: W
authors.initials: W
authors.lastname: Christen
authors.forename: Y A
authors.initials: YA
authors.lastname: Akova
authors.forename: E
authors.initials: E
authors.lastname: Messmer
authors.forename: M
authors.initials: M
authors.lastname: Pedroza-Seres
authors.forename: N
authors.initials: N
authors.lastname: Barney
authors.forename: C S
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D009877:Endophthalmitis / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D011239:Prednisolone